Further research examining the signaling events and factors that regulate normal splicing of MDM2 and also the misregulated splicing observed in cancers will be critical for identifying therapeutic strategies for treatment of tumors harboring aberrantly spliced isoforms of MDM2 and MDMX. The gene discussed is MDM2; the disease is cancer.